• 9 June 2009
  • News
  • By

Jubilant leverages on collaborations

Jubilant leverages on collaborations
Partnerships are the key to drug discovery and this seems to be a recurring theme for Jubilant Organosys over the last year which saw collaborations with companies such as Lilly and Astra Zeneca.

Jubilant Organosys Ltd is an integrated pharmaceutical industry player that provides custom research and manufacturing services (CRAMS) and drug discovery and development services.
Jubilant Organosys focuses on the pharmaceutical value chain for products and services such as exclusive synthesis, contract manufacturing, proprietary products, active pharmaceutical ingredients, generic dosage forms, drug discovery services, drug development services, chemistry services, clinical research services, steriles, non-steriles and radiopharmaceuticals.
Jubilant Organosys has five subsidiary companies in India that includes Jubilant Biosys Ltd for discovery informatics and drug discovery services; Jubilant Chemsys Ltd for medicinal chemistry; Clinsys Clinical Research Ltd for clinical research and bioavailability or bio equivalence studies; Jubilant First Trust Healthcare Ltd for high quality healthcare services and Specialty Molecules Pvt Ltd for niche expertise in continuous vapor phase halogenations reaction.
Jubilant has signed several R&D deals in 2008. In July 2008, Jubilant Biosys Ltd., Bangalore and Amgen Inc, Thousand Oaks, California, had announced a drug discovery partnership to develop a portfolio of novel drugs in new target areas across multiple therapeutic areas. Jubilant will be engaged in the development of early preclinical candidates from Amgen’s early discovery efforts for an initial term of three years, Amgen will have the responsibility for the subsequent preclinical and clinical development and their commercialization. Amgen will retain/own the drugs developed in collaboration with worldwide commercialization rights.
Commenting on the development, Shyam S Bhartia, chairman and managing director and Hari S Bhartia, co-chairman and managing director of Jubilant Organosys said, “We are very pleased to expand our relationship with Amgen. This collaboration leverages the innovation capabilities of Jubilant Biosys in pharmaceutical discovery and preclinical development. ”
In October 2008, Jubilant Organosys entered into an agreement with Eli Lilly India to form an equally-owned joint venture in India focused on providing drug development services exclusively to Jubilant and Eli Lilly partnered molecules. The joint venture based out of Bangalore is focusing on preclinical molecules and their development through phase-II clinical trials, before returning successful assets to the sponsors for further development.
In May 2009, Jubilant has signed a research collaboration agreement with AstraZeneca, focuses on delivering novel drug candidates into its preclinical pipeline.
Jubilant focus on flexible and hybrid platform of innovative discovery chemistry, biology and insilico services demonstrates its ability to customize and accelerate global drug discovery efforts led the company to clock Rs 242 crore in revenues from the services business.”

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X